Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 10/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3118598 | 0.92 | ADORA2B (0.49) | TP53ADORA1ADORA2AADORA2BADORA3 | |
| SCHEMBL3121547 | 0.90 | ADORA1 (0.44) | SMN1; SMN2TP53ADORA1ADORA2AADORA2B | |
| SCHEMBL13248141 | 0.88 | TP53 (0.57) | TSHRL3MBTL1SMN1; SMN2TP53RXFP1 | |
| SCHEMBL3114339 | 0.88 | HPGD (0.50) | TSHRL3MBTL1TP53ADORA1ADORA2A | |
| SCHEMBL13248174 | 0.87 | ADORA1 (0.44) | TSHRL3MBTL1SMN1; SMN2ADORA1ADORA2A | |
| SCHEMBL13248170 | 0.86 | SMN1; SMN2 (0.45) | TSHRL3MBTL1SMN1; SMN2TP53ADORA1 | |
| SCHEMBL13248161 | 0.86 | SMN1; SMN2 (0.45) | TSHRL3MBTL1SMN1; SMN2TP53ADORA1 | |
| SCHEMBL3108428 | 0.84 | ADORA2B (0.48) | TSHRL3MBTL1SMN1; SMN2TP53ADORA1 | |
| SCHEMBL3115385 | 0.84 | ADORA1 (0.49) | ADORA1ADORA2AADORA2BADORA3 | |
| SCHEMBL13248164 | 0.81 | TP53 (0.46) | SMN1; SMN2TP53ADORA1ADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100179128-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | SMITHKLINE BEECHAM CORPORATION | 2010-07-15 | — | — | US | disclosed |
| US-20100179128-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | SMITHKLINE BEECHAM CORPORATION | 2010-07-15 | — | — | US | disclosed |
| US-20100179128-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | SMITHKLINE BEECHAM CORPORATION | 2010-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179128-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | XDH, GPR84, GPR88 | TSHR 430/4885L3MBTL1 3898/4885SMN1; SMN2 761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.